Physician profile
Eva Salcedo
NPI 1194958017
$6,786.51
in general payments reported to CMS, 2019-2025
46 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.50 · 2021: $946 · 2022: $1,241 · 2023: $1,423 · 2024: $1,872 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $950.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $772.61 | 2021-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $575.62 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $317.02 | 2021-2025 | |
| Abbvie INC. | $282.32 | 2021-2025 | Linzess, Viberzi, Ubrelvy |
| Radius Health, INC. | $267.61 | 2023-2025 | Tymlos |
| Insulet Corporation | $264.01 | 2023-2025 | Omnipod |
| Abbott Laboratories | $255.13 | 2022-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $209.98 | 2022-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.02 | 2021-2025 | Xifaxan, Trulance |
| Mannkind Corporation | $194.77 | 2021-2025 | Afrezza |
| Amneal Pharmaceuticals LLC | $174.29 | 2020-2024 | Unithroid |
| Inspire Medical Systems, INC. | $165.94 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $135.74 | 2021-2022 | |
| Vivus LLC | $132.75 | 2021-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $129.67 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.59 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $125.92 | 2022-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Tandem Diabetes Care, INC. | $125.91 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $112.81 | 2022-2025 | Licart, Tirosint, Flector |
| Astrazeneca Pharmaceuticals LP | $108.80 | 2022-2025 | Farxiga, Airsupra |
| Esperion Therapeutics, INC. | $104.24 | 2021-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $100.72 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $94.21 | 2021-2023 | Livalo |
| Xeris Pharmaceuticals, INC. | $89.19 | 2022-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $81.14 | 2022-2025 | |
| Sanofi Pasteur INC. | $67.46 | 2020-2023 | |
| Dexcom, INC. | $66.48 | 2024 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $63.39 | 2025 | Yorvipath |
| Astellas Pharma US INC | $62.59 | 2022-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $54.95 | 2021 | |
| Antares Pharma, INC. | $45.33 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Zealand Pharma US, INC. | $40.80 | 2021-2022 | |
| Embecta Corp. | $27.51 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Verity Pharmaceuticals INC. | $27.13 | 2024 | Tlando |
| Alexion Pharmaceuticals, INC. | $26.12 | 2025 | Strensiq |
| Avvisto Therapeutics, LLC | $24.90 | 2025 | Cycloset |
| Grt US Holding, INC. | $22.93 | 2021 | |
| Horizon Therapeutics Plc | $22.17 | 2023 | Tepezza |
| Amryt Pharma Holdings LTD | $22.15 | 2022 | |
| Halozyme INC | $22.04 | 2023 | |
| Amarin Pharma, INC. | $20.08 | 2021 | |
| Boston Scientific Corporation | $19.85 | 2024 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $18.46 | 2023 | Quviviq |
| Ipsen Biopharmaceuticals, INC | $17.88 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Salcedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.